The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity

Add time:07/20/2019    Source:sciencedirect.com

Deregulation of the receptor tyrosine kinase RET has been implicated in medullary thyroid cancer, a small percentage of lung adenocarcinomas, endocrine-resistant breast cancer and pancreatic cancer. There are several clinically approved multi-kinase inhibitors that target RET as a secondary pharmacology but additional activities, most notably inhibition of KDR, lead to dose-limiting toxicities. There is, therefore, a clinical need for more specific RET kinase inhibitors. Herein we report our efforts towards identifying a potent and selective RET inhibitor using vandetanib 1 as the starting point for structure-based drug design. Phenolic anilinoquinazolines exemplified by 6 showed improved affinities towards RET but, unsurprisingly, suffered from high metabolic clearance. Efforts to mitigate the metabolic liability of the phenol led to the discovery that a flanking substituent not only improved the hepatocyte stability, but could also impart a significant gain in selectivity. This culminated in the identification of 36; a potent RET inhibitor with much improved selectivity against KDR.

We also recommend Trading Suppliers and Manufacturers of 2-AMINO-6,7-DIMETHOXYQUINAZOLIN-4-OL (cas 16175-67-0). Pls Click Website Link as below: cas 16175-67-0 suppliers

Prev:Synthesis and pharmacological evaluation of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline derivatives as sigma-2 receptor ligands
Next:Spectral correlation, antimicrobial and insect antifeedant activities of some 1-naphthyl keto-oxiranes)